drugset / Trial / NCT04691570

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT04691570

Phase 2 Completed 7 enrolled Annexon, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Timeline

Start
2021-11-10
Primary completion
2023-01-17
Completion
2023-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject ANX005 Protein / enzyme biologic Intravenous